Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
6.06
-0.05 (-0.82%)
At close: Oct 3, 2024, 4:00 PM
6.11
+0.05 (0.83%)
After-hours: Oct 3, 2024, 7:00 PM EDT
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenue of $14.42M in the quarter ending June 30, 2024, with 30.86% growth. This brings the company's revenue in the last twelve months to $49.64M, down -0.70% year-over-year. In the year 2023, Recursion Pharmaceuticals had annual revenue of $44.58M with 11.88% growth.
Revenue (ttm)
$49.64M
Revenue Growth
-0.70%
P/S Ratio
28.06
Revenue / Employee
$99,270
Employees
500
Market Cap
1.70B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 44.58M | 4.73M | 11.88% |
Dec 31, 2022 | 39.84M | 29.67M | 291.46% |
Dec 31, 2021 | 10.18M | 6.22M | 156.89% |
Dec 31, 2020 | 3.96M | 1.64M | 70.85% |
Dec 31, 2019 | 2.32M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fortrea Holdings | 3.01B |
Supernus Pharmaceuticals | 630.16M |
NovoCure | 549.96M |
Kiniksa Pharmaceuticals International, | 338.93M |
STAAR Surgical Company | 332.94M |
CareDx | 297.08M |
MannKind | 248.37M |
Arvinas | 93.30M |
RXRX News
- 1 day ago - Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment - CNBC
- 1 day ago - Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma - GlobeNewsWire
- 4 weeks ago - Recursion: Path Forward For REC-994 Remains Despite Mixed Response - Seeking Alpha
- 4 weeks ago - Recursion's blood vessel disorder drug meets main goal in mid-stage study - Reuters
- 7 weeks ago - Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals - Benzinga
- 2 months ago - CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities - GlobeNewsWire